Xue Zhu to Animals
This is a "connection" page, showing publications Xue Zhu has written about Animals.
Connection Strength
0.133
-
Zhu XY, Mardenborough LG, Li S, Khan A, Zhang W, Fan P, Jacob M, Khan S, Walker L, Ablordeppey SY. Synthesis and evaluation of isosteres of N-methyl indolo[3,2-b]-quinoline (cryptolepine) as new antiinfective agents. Bioorg Med Chem. 2007 Jan 15; 15(2):686-95.
Score: 0.019
-
Inkoom A, Ndemazie NB, Smith T, Frimpong E, Bulusu R, Poku R, Zhu X, Han B, Trevino J, Agyare E. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer. BMC Cancer. 2023 May 13; 23(1):435.
Score: 0.015
-
Ndemazie NB, Bulusu R, Zhu XY, Frimpong EK, Inkoom A, Okoro J, Ebesoh D, Rogers S, Han B, Agyare E. Evaluation of Anticancer Activity of Zhubech, a New 5-FU Analog Liposomal Formulation, against Pancreatic Cancer. Int J Mol Sci. 2023 Feb 21; 24(5).
Score: 0.015
-
Ndemazie NB, Inkoom A, Ebesoh D, Bulusu R, Frimpong E, Trevino J, Han B, Zhu X, Agyare E. Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer. BMC Cancer. 2022 Dec 22; 22(1):1345.
Score: 0.015
-
Al-Ghanim L, Zhu XY, Asong G, Ablordeppey SY. SYA 013 analogs as moderately selective sigma-2 (s2) ligands: Structure-affinity relationship studies. Bioorg Med Chem. 2019 06 15; 27(12):2421-2426.
Score: 0.011
-
Etukala JR, Zhu XY, Eyunni SV, Onyameh EK, Ofori E, Bricker BA, Kang HJ, Huang XP, Roth BL, Ablordeppey SY. Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores. Bioorg Med Chem. 2016 08 15; 24(16):3671-9.
Score: 0.009
-
Sampson D, Bricker B, Zhu XY, Peprah K, Lamango NS, Setola V, Roth BL, Ablordeppey SY. Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett. 2014 Sep 01; 24(17):4294-7.
Score: 0.008
-
Sampson D, Zhu XY, Eyunni SV, Etukala JR, Ofori E, Bricker B, Lamango NS, Setola V, Roth BL, Ablordeppey SY. Identification of a new selective dopamine D4 receptor ligand. Bioorg Med Chem. 2014 Jun 15; 22(12):3105-14.
Score: 0.008
-
Bolden S, Zhu XY, Etukala JR, Boateng C, Mazu T, Flores-Rozas H, Jacob MR, Khan SI, Walker LA, Ablordeppey SY. Structure-activity relationship (SAR) and preliminary mode of action studies of 3-substituted benzylthioquinolinium iodide as anti-opportunistic infection agents. Eur J Med Chem. 2013; 70:130-42.
Score: 0.008
-
Bolden S, Boateng CA, Zhu XY, Etukala JR, Eyunni SK, Jacob MR, Khan SI, Ablordeppey SY. CoMFA studies and in vitro evaluation of some 3-substituted benzylthio quinolinium salts as anticryptococcal agents. Bioorg Med Chem. 2013 Nov 15; 21(22):7194-201.
Score: 0.008
-
Boateng CA, Zhu XY, Jacob MR, Khan SI, Walker LA, Ablordeppey SY. Optimization of 3-(phenylthio)quinolinium compounds against opportunistic fungal pathogens. Eur J Med Chem. 2011 May; 46(5):1789-97.
Score: 0.006
-
Ablordeppey SY, Altundas R, Bricker B, Zhu XY, Kumar EV, Jackson T, Khan A, Roth BL. Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. Bioorg Med Chem. 2008 Aug 01; 16(15):7291-301.
Score: 0.005
-
Mardenborough LG, Zhu XY, Fan P, Jacob MR, Khan SI, Walker LA, Ablordeppey SY. Identification of bis-quindolines as new antiinfective agents. Bioorg Med Chem. 2005 Jun 02; 13(12):3955-63.
Score: 0.004